FBIO

Business Context and Reporting Period

Company: Fortress Biotech, Inc. (FBIO)
Filing Type: Form 10-K (Annual Report)
Period Ended: December 31, 2025
Business Model: Fortress operates as a biopharmaceutical holding company that acquires and advances assets through a network of subsidiaries and partner companies. Its primary revenue stream comes from the commercialization of dermatology products via its partner, Journey Medical Corporation (Journey). The company also holds interests in various development-stage assets across oncology, rare diseases, and infectious diseases.

Key Financial Metrics

Material Changes vs. Prior Period

• Revenue Growth: Net revenue increased 10% to $63.3 million, driven primarily by the commercial launch of Emrosi (rosacea treatment) which generated $14.7 million in 2025. This offset a $6.5 million decline in Accutane revenue due to generic competition.
• Improved Net Position: Net loss attributable to Fortress improved significantly from a loss of $46.0 million in 2024 to a net income of $6.8 million in 2025. This turnaround was largely due to a $27.1 million gain from the deconsolidation of Checkpoint Therapeutics (sold to Sun Pharma) and a $15.1 million increase in the fair value of the investment in Crystalys Therapeutics.
• Expense Reduction: Research and Development (R&D) expenses decreased 79% to $11.9 million, primarily due to the deconsolidation of Checkpoint and reduced costs at Mustang and Journey following the approval of Emrosi. Selling, General, and Administrative (SG&A) expenses increased 10% to $96.4 million, driven by operational costs for the Emrosi launch.
• Debt Management: The company repaid $5.5 million of principal on its Oaktree credit facility using proceeds from the Checkpoint sale. The outstanding principal balance on the Oaktree note was $29.8 million as of December 31, 2025.

Guidance, Outlook, and Material Events

• Subsequent Events (Post-2025):
  • PRV Sale: In March 2026, Cyprium closed the sale of a Rare Pediatric Disease Priority Review Voucher (PRV) for $205 million following the FDA approval of ZYCUBO (Menkes disease treatment) in January 2026. The company expects to receive at least $100 million from this transaction.
  • Debt Covenant Relief: Following the PRV sale, Fortress amended its Oaktree credit agreement. The minimum liquidity requirement was lowered to $2.0 million, and the Minimum Net Sales Test and Capital Raise covenants were waived, provided the loan balance remains below $15.0 million.
  • Checkpoint Monetization: Fortress received $28.0 million in cash proceeds from the sale of Checkpoint to Sun Pharma in May 2025 and retains a 2.5% royalty on UNLOXCYT sales.
• Product Pipeline:
  • Emrosi: Launched in March 2025; faces potential generic competition (Lupin filed a Paragraph IV certification in February 2026).
  • Triplex (Helocyte): Phase 2 trials ongoing for CMV control in stem cell transplant and HIV patients; topline data expected in H1 2026.
  • CAEL-101 (AstraZeneca): Phase 3 trials for AL amyloidosis did not meet primary endpoints but showed meaningful improvement in a prespecified subgroup; EMA review ongoing.
• Risks and Contingencies:
  • Financing Constraints: Dividends on Series A Preferred Stock were paused in July 2024. Consequently, the company is ineligible to use Form S-3 for equity offerings until dividends are paid and current obligations are met.
  • Debt Covenants: The company must maintain minimum liquidity and meet net sales targets for Journey to avoid default on its Oaktree facility, though recent amendments provide relief contingent on the PRV sale proceeds.
  • Generic Competition: Significant portion of Journey's revenue comes from products without patent protection (Accutane, Targadox, Exelderm, Luxamend), exposing the company to price erosion.

Investor Verification Checklist

• PRV Proceeds Distribution: Verify the timing and amount of cash distribution from the $205 million PRV sale to Fortress and confirm the repayment of the Oaktree debt to $15.0 million or less.
• Emrosi Sales Trajectory: Monitor quarterly sales of Emrosi to ensure Journey meets the Minimum Net Sales Test covenants ($60M - $80M thresholds) if the PRV proceeds do not fully waive the covenant.
• Series A Preferred Dividends: Assess the company's ability to resume dividend payments on Series A Preferred Stock to regain eligibility for Form S-3 equity offerings.
• Generic Litigation: Track the outcome of the patent infringement lawsuit filed by Journey against Lupin regarding Emrosi, as a loss could accelerate revenue decline.
• Checkpoint Royalties: Monitor the commercial performance of UNLOXCYT by Sun Pharma to estimate future royalty income (2.5% of net sales).